Pipeline
Addressing Cancer and Beyond
We are advancing a robust pipeline of clinical and preclinical programs. Tmod™ technology is modular, flexible, and can be applied to a host of indications – in cancers and beyond – where selective cell targeting is important. Our initial programs target solid tumor cancers.
Our Pipeline
Program: A2B694
Target: MSLN
Indications: Ovarian, Mesothelioma, Pancreatic, Colorectal, Lung, and Gastroesophageal Cancers
| DISCOVERY | IND ENABLING | PHASE 1 | PHASE 2 |
Program: A2B395
Target: EGFR
Indications: Head and Neck, Kidney, Breast, and Lung Cancers
| DISCOVERY | IND ENABLING | PHASE 1 | PHASE 2 |
Program: A2B543
Target: MSLN
Booster: IL-12
Indications: Ovarian, Mesothelioma, Pancreatic, Colorectal, and Lung Cancers
| DISCOVERY | IND ENABLING | PHASE 1 | PHASE 2 |
Program: A2B356
Target: Undisclosed
Indications: Hematological Cancers
| DISCOVERY | IND ENABLING | PHASE 1 | PHASE 2 |
Our Clinical Programs
A2B694
A2B694 is a Tmod™ CAR T-cell therapy targeting tumors that express mesothelin (MSLN) but lack the HLA-A*02 antigen. A2B694 is being studied in our clinical trial EVEREST-2. EVEREST-2 is designed to evaluate patients with recurrent, unresectable, locally advanced, or metastatic colorectal, non-small cell lung, pancreatic, or ovarian cancer, mesothelioma, or other solid tumors that express MSLN.
The modularity of the Tmod™ platform enables vast pipeline expansion opportunities. Additional therapies can be created by varying activator and blocker combinations. Further information about this study can be found here: NCT06051695
A2B395
A2B395 is an allogeneic Tmod™ CAR T-cell therapy targeting tumors that express epidermal growth factor receptor (EGFR) but lack the HLA-A*02 antigen. A2B395 is being studied in our clinical trial DENALI-1. DENALI-1 is designed to evaluate patients with recurrent, unresectable, locally advanced, or metastatic colorectal cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, or renal cell carcinoma, or other solid tumors associated with EGFR expression.
The modularity of the Tmod™ platform enables vast pipeline expansion opportunities. Additional therapies can be created by varying activator and blocker combinations. Further information about this study can be found here: NCT06682793
A2B530
EVEREST-1 has now closed enrollment. Further information about this study can be found here: NCT05736731